Cost-Effectiveness of a Technology-Enhanced Diabetes Care Management Program in Mexico

被引:6
|
作者
Gilmer, Todd [1 ]
Burgos, Jose Luis [1 ]
Cecilia Anzaldo-Campos, Maria [2 ]
Vargas-Ojeda, Adriana [3 ]
机构
[1] Univ Calif San Diego, 9500 Gilman Dr, La Jolla, CA 92093 USA
[2] Inst Mexican Seguro Social, Hosp Gen Reg 20, Tijuana, Baja California, Mexico
[3] Autonomous Univ Baja California, Tijuana, Baja California, Mexico
关键词
cost-effectiveness; diabetes; technology; BLOOD-GLUCOSE; METABOLIC-CONTROL; MEDICAL-CARE; TYPE-2; MELLITUS; MODEL; PREVALENCE; BURDEN; HEALTH; IMPACT;
D O I
10.1016/j.vhri.2018.12.006
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The prevalence of diabetes has increased substantially in Mexico over the last 40 years, leading to significant impacts on population health and the healthcare system. Technology-based solutions may improve diabetes outcomes in areas where lack of efficient transportation creates barriers to care. Objectives: To estimate the lifetime cost-effectiveness of a technology-based diabetes care management program from the perspective of the Mexican healthcare system. Methods: Clinical outcomes and cost data from a 3-arm randomized clinical trial of Dulce Wireless Tijuana, a diabetes care management program incorporating short-term mobile technology, were used as inputs in a validated simulation model for type 2 diabetes. Study arms included a control group (CG), Project Dulce diabetes care management (PD), and Project Dulce with technology enhancement (PD-TE). Results: Intervention costs were $1448 for PD and $1740 for PD-TE compared with $740 for CG. Both intervention arms increased quality-adjusted life-years and costs. The incremental cost-effectiveness ratio for PD was $1635 and for PD-TE was $2220, both compared with CG. The incremental cost-effectiveness ratio for PD-TE versus PD was $4299. The results were sensitive to the time horizon. The PE and PD-TE interventions were cost-effective under time horizons of 15 to 20 years, but were not cost-effective under time horizons of 5 to 10 years. Conclusions: Both the PD and PD-TE were highly cost-effective from a Mexican health system perspective. Considering the economic impact of the diabetes epidemic and the widespread use of cellular technology in Mexico, implementation of PD-TE is warranted.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 50 条
  • [41] Cost-effectiveness of the Victorian Stroke Telemedicine program
    Kim, Joosup
    Tan, Elise
    Gao, Lan
    Moodie, Marj
    Dewey, Helen M.
    Bagot, Kathleen L.
    Pompeani, Nancy
    Sheppard, Lauren
    Bladin, Christopher F.
    Cadilhac, Dominique A.
    AUSTRALIAN HEALTH REVIEW, 2022, 46 (03) : 294 - 301
  • [42] Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was
    Rittenhouse, Brian E.
    Alolayan, Sultan
    Eguale, Tewodros
    Segal, Alissa R.
    Doucette, Joanne
    DIABETES OBESITY & METABOLISM, 2024, 26 (11) : 5097 - 5106
  • [43] Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management
    Schultz, Bob G.
    Tilton, Jessica
    Jun, Julie
    Scott-Horton, Tiffany
    Quach, Danny
    Touchette, Daniel R.
    VALUE IN HEALTH, 2021, 24 (04) : 522 - 529
  • [44] Comprehensive cost-effectiveness of diabetes management for the underserved in the United States: A systematic review
    Bosetti, Rita
    Tabatabai, Laila
    Naufal, Georges
    Menser, Terri
    Kash, Bita
    PLOS ONE, 2021, 16 (11):
  • [45] Cost-Effectiveness of the Hepatitis C Self-Management Program
    Groessl, Erik J.
    Sklar, Marisa
    Laurent, Diana D.
    Lorig, Kate
    Ganiats, Theodore G.
    Ho, Samuel B.
    HEALTH EDUCATION & BEHAVIOR, 2017, 44 (01) : 113 - 122
  • [46] Cost-effectiveness of a disease management program for early childhood caries
    Samnaliev, Mihail
    Wijeratne, Rashmi
    Kwon, Eunhae Grace
    Ohiomoba, Henry
    Ng, Man Wai
    JOURNAL OF PUBLIC HEALTH DENTISTRY, 2015, 75 (01) : 24 - 33
  • [47] Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis
    Kahn, Richard
    Alperin, Peter
    Eddy, David
    Borch-Johnsen, Knut
    Buse, John
    Feigelman, Justin
    Gregg, Edward
    Holman, Rury R.
    Kirkman, M. Sue
    Stern, Michael
    Tuomilehto, Jaakko
    Wareham, Nick J.
    LANCET, 2010, 375 (9723) : 1365 - 1374
  • [48] Cost-effectiveness of the adherence with recommendations for clinical monitoring of patients with diabetes
    Corrao, Giovanni
    Rea, Federico
    Mancia, Giuseppe
    Perseghin, Gianluca
    Merlino, Luca
    Martini, Nello
    Carbone, Simona
    Carle, Flavia
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (11) : 3111 - 3121
  • [49] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    DIABETES OBESITY & METABOLISM, 2014, 16 (04) : 366 - 375
  • [50] Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes
    Li, Te
    Wan, Xu
    Ma, Jin
    Wu, Bin
    ADVANCES IN THERAPY, 2018, 35 (12) : 2214 - 2223